Dysport as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis
-
- STATUS
- Recruiting
-
- End date
- Apr 1, 2023
-
- participants needed
- 90
-
- sponsor
- Johns Hopkins University
Summary
This study evaluates the combined effect of botulinum toxin A (administered as Dysport (Ipsen Pharmaceuticals)) and bracing in children with adolescent idiopathic scoliosis. Two thirds of patients will be treated with Dysport and bracing, while the remaining patients will be treated with placebo and bracing.
Description
Adolescent idiopathic scoliosis (AIS) is lateral curvature of the spine with an unknown cause in children 10-16 years old. Without treatment, skeletally immature children with idiopathic curves of 20-40 risk curve progression. Treatment of these patients is focused on either observation or bracing. Although bracing has been shown to be more effective than observation, success is contingent on patient adherence and has the potential for further optimization with adjunct therapies.
Little research is available concerning adjunct therapies that may be used during bracing of AIS patients. One therapy in particular, abobotulinumtoxinA (BTX) injection, has been poorly studied. Injection of BTX into the paraspinal musculature of the concave aspect of the major curve may result in a more malleable curve and thus optimize brace treatment. If BTX injections are found to improve outcomes in this way, a new standard of nonoperative care could be established for AIS patients, potentially reducing the number of patients who undergo surgery.
The aim of this study is to assess whether BTX injections (administered as Dysport (Ipsen Pharmaceuticals)) in the paraspinal musculature at the site of the major scoliotic curve decrease curve progression in skeletally immature AIS patients who are concurrently treated with bracing. Dysport will be evaluated primarily as an adjunct treatment to bracing.
Hypotheses
- Dysport injections into the concave-side paraspinal muscles will decrease the rate of curve progression, with a lower rate of curve progression in patients treated with both Dysport injections and bracing compared with those treated with only bracing.
- Quantitative physical and mental health scores will improve to a greater extent in patients treated with Dysport and bracing compared with patients treated with only bracing.
Details
| Condition | Adolescent Idiopathic Scoliosis |
|---|---|
| Treatment | placebos, AbobotulinumtoxinA, Custom Thoracolumbosacral Orthosis |
| Clinical Study Identifier | NCT03935295 |
| Sponsor | Johns Hopkins University |
| Last Modified on | 1 October 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer